Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The PACMAN-hu19 Trial: a Phase I/II Study to Investigate the Safety and Feasibility of Point-of-care Human CD19 Targeting CAR T-cells in Pediatric and Young Adult Patients With Relapsed or Refractory B-cell Malignancies

NCT07020260 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.

NCT NCT07020260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07020260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The PACMAN-hu19 Trial: a Phase I/II Study to Investigate the Safety and Feasibility of Point-of-care Human CD19 Targeting CAR T-cells in Pediatric and Young Adult Patients With Relapsed or Refractory B-cell Malignancies
Lead sponsor
Princess Maxima Center for Pediatric Oncology
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
September 1, 2028
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma